Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors Read more about Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial) Read more about Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
Nutrition and Pharmacological Algorithm for Oncology Patients Study Read more about Nutrition and Pharmacological Algorithm for Oncology Patients Study
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors Read more about A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients Read more about Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients
FPA150 in Patients With Advanced Solid Tumors Read more about FPA150 in Patients With Advanced Solid Tumors
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Read more about Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer Read more about Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer Read more about Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers Read more about A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers